• Radiation Oncology Journal
• /
• 제10권2호
• /
• pp.267-275
• /
• 1992

원격조정 고선량 근접치료는 새로운 각광받는 테크놀로지이다. 이에, 저자들은 3년간의 서울중앙병원의 590횟수, 116 환자를 대상으로 고선량 근접치료의 그 시술과 임상적 결과를 평가해 보고자 한다 자궁경부암 58 환자와 비인두강암 26 환자의 관내 방사선치료 471 횟수, 식도암 12 환자, 내 기관지암 11 환자, 클라스킨 종양 1 환자의 관내 방사선치료 79 횟수와 유방암 4 환자, 육종 1 환자, 요도암 1 환자의 조직내 방사선치료 40 횟수가 1989년 9월에서 1992년 8월 사이에 시행되어졌다. 추적 관찰 기간은 1 개월에서 35개월이었고, 그 중간 기간은 7개월이었다. 조직내 방사선치료를 제외한 모든 시술은 국소 마취로 시행하였고, 모든 환자에서 급성 합병증은 생기지 않았다. 또한, 6 환자를 제외하고는 모두 계획 선량대로 치료를 마칠 수가 있었다. 자궁경부암 58 환자에서, 비인두강암 26 환자 중 20 환자에서 완전 관해가 일어났으며, 증상 완화 목적으로 치료한 15 환자에서 $80{\%}$의 환자에서 소기의 목적을 이룰 수 있었다. 이 논문에서 원격조정 고선량 근접치료의 자세한 시술과 그에 따른 결과를 설명할 것이다. 이 치료의 생물학적인 효과와 적당한 선량/선량 횟수/분할치료를 평가하기 위해, 우리는 더욱 긴 추적 관찰을 시행하여야 하며, 이 새로운 근접치료 시술이 저선량 근접치로 시술보다 효과적이고 외래 환자로 통근 치료가 가능하며, 안전한 치료 방법이라고 생각하고 있다.

• 대한방사선기술학회지:방사선기술과학
• /
• 제39권4호
• /
• pp.565-570
• /
• 2016

방사성 요오드($^{131}I$) 치료는 분화성 갑상선암 환자에서 재발을 감소시키고 생존률을 증가시키나, 환자에서 방출되는 방사능으로 인하여 피폭을 야기시킬 수 있으므로 환자로부터 발생되는 방사선량률을 측정하는 것이 방사선안전관리 측면에서 중요하다. 방사성 요오드($^{131}I$) 치료시 널리 사용되는 측정기 중 전리함과 GM계수관으로 측정된 방사선량률의 감도와 측정효율을 구하였다. 방사성 요오드($^{131}I$)를 150mCi 경구투여 받은 분화성 갑상선암 환자의 상복부로부터 1 m거리에서 경과 시간에 따라 방사선량률을 측정하였다. 시간에 따른 변화를 직접적으로 비교한 결과, 고선량률에서의 감도와 측정효율은 GM계수관보다 전리함이 높게 나타났고, 통계적으로 유의하였다(p<0.05). 저선량률에서의 감도와 측정효율은 GM계수관보다 전리함이 낮게 나타났지만 통계적으로 유의한 차이를 나타내지 않았다(p>0.05). 방사성 요오드($^{131}I$) 치료시에 검 교정이 완료된 전리함과 GM계수관으로 정확하고 신속한 방사선량률을 측정하여 환자에게 설명함으로써 방사성 요오드 치료 후 퇴원하는 환자에게 환자가족 또는 주변 사람들에게 미칠 수 있는 방사선피폭을 예측하고, 불필요한 예단을 줄여줄 수 있을 것이다.

• Journal of Trauma and Injury
• /
• 제26권3호
• /
• pp.198-206
• /
• 2013

Purpose: This study was performed to calculate and analyze the effective radiation doses from computed tomography (CT) and radiologic intervention in patients in the emergency department (ED) with trauma critical pathway (CP) activation and further to estimate the lifetime attributable risks (LARs) for the incidence of and mortality from cancers induced by the radiation dose. Methods: Through a retrospective electrical chart review of 104 injured patients who trauma critical pathway were activated from November 2012 to March 2013, we calculated effective radiologic doses by taking the product of the dose-linear product of the scan and the conversion coefficient. After a determination of the image results, we divided the patients into two groups, negative or positive, and calculated the effective dose for each group. With these results, we estimated the LARs for the incidence of and the mortality from cancers by using the table in the Biologic Effects of Ionizing Radiation (BEIR)-VII report. Results: A total of 76 patients were enrolled. The mean age was $49.0{\pm}8.5$ years. The mean injury severity score (ISS) was $12.7{\pm}8.4$. The cumulative effective dose (CED) for individual patients varied from 2.8 mSv to 238.8 mSv, and the mean was $47.6{\pm}39.9$ mSv. The CED in patients with an $ISS{\geq}16$($63.2{\pm}26.6$ mSv) was higher than that of patients whose ISS<16($33.5{\pm}23.1$ mSv) (p<0.001). The CED in patients who were treated with surgery or intervention($69.0{\pm}45.2$ mSv) was higher than that of patients who were treated conservatively($33.6{\pm}22.4$ mSv) (p<0.001). The LARs for cancer incidence and mortality were $328.5{\pm}308.6$ and $189.0{\pm}159.3$ per 100,000 people, respectively. Conclusion: The CED and the LAR for trauma CP-activated patients in the ED were significant, so efforts should be made to decrease the effective dose received by severely injured patients.

• Radiation Oncology Journal
• /
• 제33권3호
• /
• pp.242-249
• /
• 2015

Purpose: The purpose of this study is to compare the dosimetry of electron beam (EB) plans and three-dimensional helical tomotherapy (3DHT) plans for the patients with left-sided breast cancer, who underwent breast conserving surgery. Materials and Methods: We selected total of 15 patients based on the location of tumor, as following subsite: subareolar, upper outer, upper inner, lower lateral, and lower medial quadrants. The clinical target volume (CTV) was defined as the area of architectural distortion surrounded by surgical clip plus 1 cm margin. The conformity index (CI), homogeneity index (HI), quality of coverage (QC) and dose-volume parameters for the CTV, and organ at risk (OAR) were calculated. The following treatment techniques were assessed: single conformal EB plans; 3DHT plans with directional block of left anterior descending artery (LAD); and 3DHT plans with complete block of LAD. Results: 3DHT plans, regardless of type of LAD block, showed significantly better CI, HI, and QC for the CTVs, compared with the EB plans. However, 3DHT plans showed increase in the $V_{1Gy}$ at skin, left lung, and left breast. In terms of LAD, 3DHT plans with complete block of LAD showed extremely low dose, while dose increase in other OARs were observed, when compared with other plans. EB plans showed the worst conformity at upper outer quadrants of tumor bed site. Conclusion: 3DHT plans offer more favorable dose distributions to LAD, as well as improved target coverage in comparison with EB plans.

• Nuclear Engineering and Technology
• /
• 제55권1호
• /
• pp.254-260
• /
• 2023

Skeletal metastases are common in patients suffering from various primary cancers. Radiopharmaceuticals are an effective option for bone pain palliation. In this work, the radiation absorbed dose of ¹⁷⁷Lu-EDTMP radiopharmaceutical was estimated for adult man based on biodistribution data in Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied. The results shows that about 46% of injected activity is cumulated on the surface of the trabecular and cortical bones. Radiation absorbed doses of red bone marrow and osteogenic cells were estimated to about 1.1 and 6.2 mGy/MBq, respectively. The maximum administrated activity was obtained 27 MBq/kg of body weight with an effective dose of 0.23 mSv/MBq. The results were compared with other available data from literature. This study indicated that ¹⁷⁷Lu-EDTMP provides therapeutic efficacy for achieving bone pain palliation with low undesired dose to other normal organs.

• Radiation Oncology Journal
• /
• 제16권3호
• /
• pp.265-274
• /
• 1998

목적 : 비소세포성 폐암에서 새로운 치료방법으로 대두되고 있는 3차원 입체조형 방사선 치료(Three dimensional conformal radiotherapy, 3DCRT)의 임상적용 가능성과 기존의 치료법에 비한 장점을 찾고자 1994년부터 전향적 연구를 시행하였다. 본 연구는 1) 가장 효과적인 3차원 입체조형 치료 방법의 개발, 2) 가능한 총 치료 선량증가, 3) 선량 증가에 따른 방사선 폐렴 발생 위험군 예측, 4) 선량증가에 따른 국소관해 및 생존율 향상을 목적으로 하였다. 대상 및 방법 : 1996년 12월까지 수술이 불가능하다고 판정된 95명의 환자(stage I: 4명, stage II; 1명, stage IIIa; 14명, stage IIIb; 76명)에 대하여 3차원 입체조형 치료를 시행하였다. 3차원입체조형 치료를 위하여 고정기구를 이용하여 앙와위 혹은 복와위 상태로 자세를 고정한 다음 CT-simulator를 이용하여 5 mm간격으로 CT 영상을 얻고 GTV (Gross Tumor Volume), CTV (Clinical Target Volume), PTV(Planning Target Volume)를 정한 후 3차원 치료계획용 컴퓨터를 이용하여 치료계획을 세웠다. 방사선 치료는 육안적 종양과 림프절을 포함하는 부위에 36-40 Gy를 AP-PA로 치료한 후 25-34 Gy의 3차원 입체조형 치료를 추가조사하여 총 65-70 Gy를 시행하였다. 이중 78명 (82.1$\%$)의 환자는 2회의 MVP (Mitomycin C, Vinblastine, Cisplatin) 복합항암요법을 동시에 시행하였다. 3차원 입체조형 치료 계획은 1) 표적 부위의 3차원 선량분포, 2) DVH (Dose Volume Histogram), 3) NTCP (Normal Tissue Complication Probability)를 이용하여 기존의 2차원 통상 치료 계획과 비교하였다. 결과 : 78명의 환자에서는 4-8 조사영역을 이용하는 비동일 평면 입체조형 치료 (Non-coplanar 3DCRT) 방법을 사용하였으며 17명에서는 Coplanar segmented 3DCRT 방법으로 치료하였다. 거의 모든 환자에서 표적부위에 100$\%$의 선량 조사가 가능하였으며 심장에 대한 DVH 분석결과 좌폐하엽 부위 종양 치료시에는 특히 3차원 입체조형 치료가 심장 선량을 줄여줌을 알수 있었다. 3차원 입체조형 치료에 의한 동측폐의 NTCP 평균값은 0.26 (0.17-0.43)으로 2차원 통상 치료의 NTCP 평균값 0.38 (0.27-0.66)에 비하여 부작용이 생길 확률이 32$\%$ 줄어들었다. 치료 결과는 26$\%$(25/95)의 환자에서 완전관해를 보였으며 53$\%$ (50/95)에서는 부분관해를 보여 전체 79$\%$의 환자에서 부분관해 이상의 반응을 보였다. 1기와 2기 환자 5명을 제외한 3기 환자 90명의 1년과 2년 생존율은 62.6$\%$와 35.2$\%$로 같은 기간에 2차원 통상치료로 치료받은 환자의 1년과 2년 생존율 51.9$\%$와 26.8$\%$에 비하여 다소 증가 되었으나 통계적으로 유의한 차이를 보이지는 않았다. 치료후 19명 (Grade 1:8, Grade 2:11)의 환자에서 방사선 폐렴이 발생하였으나 steroid 치료후 모두 호전되었으며 치료 후 발생하는 방사선 폐렴을 예측할 수 있는 가장 좋은 지표는 동측폐에 대한 NTCP 값이었다 (35$\%$ vs 22$\%$). 결론 : 이상의 결과 폐암에 대한 3차원 입체조형 방사선 치료는 기존의 치료법에 비하여 부작용의 증가 없이 총 방사선량을 증가시킬 수 있는 좋은 방법으로 생각되며 방사선 폐렴의 예측인자로는 동측폐에 대한 NTCP 값이 매우 유용한 것으로 보여진다. 향후 NTCP 값에 따른 선량증가 연구와 이에 따른 생존율의 증가에 대한 연구가 더 진행되어야 할 것이다.

• 대한방사선기술학회지:방사선기술과학
• /
• 제33권3호
• /
• pp.283-288
• /
• 2010

한국인의 신체 특성에 맞는 방사선치료 선량 평가를 위해 한국표준여성에 기초하여 수학적 모의피폭체를 제작하였다. 이후 자궁을 선원장기로 하여 자궁경부암 근접치료 시 발생할 것으로 예상되는 자궁 및 주변장기의 흡수선량과 치료환자에 근접한 사람의 선량을 평가하였다. 시뮬레이션을 위하여 방사성핵종은 자궁경부 근접치료에 유용하게 사용되는 $^{192}Ir$을 선정하였고, 초기 방사능 1 Ci를 투여하는 것으로 가정하였다. 그 결과 선원장기인 자궁에 4.92E-14 Gy/Ci를 나타냈으며, 치료 환자로부터 거리에 따른 사람의 선량은 전방 30 cm 거리에서 1.24E-07 Sv를 나타났다.

• Radiation Oncology Journal
• /
• 제36권4호
• /
• pp.332-340
• /
• 2018

Purpose: To retrospectively analyze dosimetric parameters of volumetric-modulated arc therapy (VMAT) and three-dimensional conformal radiotherapy (3D-CRT) delivered to extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue in the stomach (gastric MALT lymphoma) to find out advantages of VMAT and conditions for definite benefits of VMAT. Materials and Methods: Fifty patients with stage I-II gastric MALT lymphoma received VMAT (n = 14) or 3D-CRT (n = 36) between December 2005 and April 2018. Twenty-seven patients were categorized according to whether the planning target volume (PTV) overlaps kidney(s). Dosimetric parameters were analyzed by dose-volume histogram. Results: Radiation dose to the liver was definitely lower with VMAT in terms of mean dose (p = 0.026) and V₁₅ (p = 0.008). The V₁₅ of the left kidney was lower with VMAT (p = 0.065). For those with PTV overlapping kidney(s), the left kidney V₁₅ was significantly lower with VMAT. Furthermore, the closer the distance between the PTV and kidneys, the less the left kidney V₁₅ with VMAT (p = 0.037). Delineation of kidney(s) by integrating all respiratory phases had no additional benefit. Conclusions: VMAT significantly increased monitor units, reduced treatment time and radiation dose to the liver and kidneys. The benefit of VMAT was definite in reducing the left kidney V₁₅, especially in geometrically challenging conditions of overlap or close separation between PTV and kidney(s).

• 한국의학물리학회:학술대회논문집
• /
• 한국의학물리학회 2003년도 제27회 추계학술대회
• /
• pp.63-63
• /
• 2003

Purpose: Planning target volume (PTV) for tumors in abdomen or thorax includes enough margin for breathing-related movement of tumor volumes during treatment. We developed a simple and handy method, which can reduce PTV margins in patients with moving tumors, respiratory motion reduction device system (RMRDs). Materials and Methods: The patients clinical database was structured for moving tumor patients and patient setup error measurement and immobilization device effects were investigated. The system is composed of the respiratory motion reduction device utilized in prone position and abdominal presser (strip device) utilized in the supine position, moving phantom and the analysis program, which enables the analysis on patients setup reproducibility. It was tested for analyzing the diaphragm movement and CT volume differences from patients with RMRDs, the magnitude of PTV margin was determined and dose volume histogram (DVH) was computed using a treatment planning software. Dose to normal tissue between patients with RMRDs and without RMRDs was analyzed by comparing the fraction of the normal liver receiving to 50% of the isocenter dose(TD50). Results: In case of utilizing RMRDs, which was personally developed in our hospital, the value was reduced to $5pm1.4 mm$, and in case of which the belt immobilization device was utilized, the value was reduced to 3$pm$0.9 mm. Also in case of which the strip device was utilized, the value was proven to reduce to $4pm.3 mm$0. As a result of analyzing the TD50 is irradiated in DVH according to the radiation treatment planning, the usage of the respiratory motion reduction device can create the reduce of 30% to the maximum. Also by obtaining the digital image, the function of comparison between the standard image, automated external contour subtraction, and etc were utilized to develop patients setup reproducibility analysis program that can evaluate the change in the patients setup. Conclusion: Internal organ motion due to breathing can be reduced using RMRDs, which is simple and easy to use in clinical setting. It can reduce the organ motion-related PTV margin, thereby decrease volume of the irradiated normal tissue.

• Radiation Oncology Journal
• /
• 제7권2호
• /
• pp.227-233
• /
• 1989

From April 1986 to Dec 1988, fifty one patients with carcinoma of lung were treated by radiation therapy in Department of Therapeutic Radiology, Yeungnam University Hospital Of the 51 patients, $31(61\%)$ were squamous cell ca, $8(15.7\%)$ were small cell ca, and remained $4(7.9\%)$ were other cell types. Total radiation dose was average $64Gy (60\~75 Gy)$ for group A and 45Gy $(40\~59Gy)$ for group B. The mass regression and the response of airway obstruction to radiation therapy was established on the basis of follow up chest X-ray. The mass regression above $50\%$ of total volume was noted in 23 patients $(74.2\%)$ among 31 patients and the difference between two groups was not seen. In squamous cell ca, however, the mass regression rate (above $50\%$ of total volume) was $83.3\%$ (10/12) in group A compared to $50\%$ (3/6) in group B(p<0.05). The alleviation of airway obstruction was noted as follows. In group A, CR $42.9\%$, PR $35.7\%$, no response $21.4\%$ and in group B, CR $55.6\%,\;PR\;33.3\%$, no response $11.1\%$. But, in squamous cell ca, responsiveness is higher than group B. The study indicates that the importance of higher radiation dose in the management of primary tumor mass and airway obstruction caused by lung cancer especially squamous cell ca. So, meticulous treatment planning and multimodality combination therapy without increasing si.do elect or complication is recommended in management of inoperable bronchogenic carcinoma.